Home
About
Overview
Sharing Data
ORCID
Help
History (16)
From cell surface to nucleus: CCRL2 regulates response to hypomethylating agents in myelodysplastic syndromes.
[Spain, France, Germany, Italy].
Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers.
The Context-Dependence of Mutations: A Linkage of Formalisms.
Reasons for Lack of Diagnostic Colonoscopy After Positive Result on Fecal Immunochemical Test in a Safety-Net Health System.
See All 16 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Search Results (30)
More Search Options
Match
Type
Why
Szmulewitz, Russell Z.
Person
Why?
Prostatic Neoplasms, Castration-Resistant
Concept
Why?
Stadler, Walter M.
Person
Why?
Skolarus, Ted
Person
Why?
Patnaik, Akash
Person
Why?
Ratain, Mark J.
Person
Why?
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
Academic Article
Why?
A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).
Academic Article
Why?
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer.
Academic Article
Why?
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
Academic Article
Why?
Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer.
Academic Article
Why?
Adoption of Abiraterone and Enzalutamide by Urologists.
Academic Article
Why?
Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
Academic Article
Why?
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
Academic Article
Why?
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.
Academic Article
Why?
Per Page
15
25
50
100
Page
of 2
Next
Prev
Search Criteria
Prostatic Neoplasms Castration Resistant
Filter by Type
All
(115)
People
(30)
Research
(84)
Concepts
(1)
_
Click "Why?" to see why an item matched the search.